Clinical Trial Update: A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528) [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates infliximab (Remicade) for moderate-to-severe chronic plaque psoriasis in a Middle Eastern population. The study has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2010-03-09